New radiation therapy approach for advanced lung cancer with Navelbine®

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of escalating radiation doses to tumors and lymph nodes in patients with locally advanced non-small cell lung cancer (NSCLC). It compares an inhomogeneous dose distribution, guided by FDG-PET positive areas, to a standard homogeneous dose spread. The goal is to determine if this targeted approach can improve treatment outcomes. Patients will receive either the escalated or standard radiation treatment as part of their care plan.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically or cytologically proven locally advanced NSCLC stage IIB to IIIB
* Performance status 0-1
* Able to comply with treatment and follow study and follow-up procedures
* Women must have negative pregnancy test
* Signed, informed consent
* Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two normal tissue must be available

Exclusion Criteria:

* Any unstable systemic disorder (including infection , unstable angina, congestive heart failure , severe liver , kidney or metabolic disease)
* Need for nasal oxygen
* Former thoracic radiotherapy, unless there is no significant overlap with previous fields
* Any other active malignant disease
* Unable to take oral medications or needing intravenous nutrition
* Ulcer
* Nursing women

Where it's running

• Aarhus University Hospital
  Aarhus, Denmark Recruiting
• Herlev University Hospital
  Herlev, Denmark Recruiting
• Department of Oncology, Odense University Hospital
  Odense, Denmark Recruiting
• Department of Oncology, Vejle Hospital
  Vejle, Denmark Recruiting
• Aalborg University Hospital
  Aalborg, Denmark Not yet recruiting
• Rigshospitalet
  Copenhagen, Denmark Not yet recruiting

Study contacts

• Study coordinator: Olfred Hansen, MD
• Email: olfred.hansen@rsyd.dk
• Phone: +4565411867

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519

  This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.

  Recruiting at 2 sites Phase 1 Aktis Oncology, Inc. · Miami, Florida and 1 other locations · NCT07887971

• SumMET: Targeted radioligand therapy for c-MET–positive solid tumors

  This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.

  Recruiting at 2 sites Phase 1/2 Full-Life Technologies UK Limited · Minneapolis, Minnesota and 1 other locations · NCT07873450

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors

  A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07793500

• NXP900 with Lorlatinib in ALK-positive NSCLC

  This study tests whether adding NXP900 to lorlatinib helps people with ALK-positive non-small cell lung cancer who have already received prior therapy.

  Recruiting Phase 1 Nuvectis Pharma, Inc. · Fairfax, Virginia · NCT07784959

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.